Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,236.00-0.99%ETH$2,242.59-0.43%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
Bristol-Myers Squibb Company logo

NYSE · BMY

Bristol-Myers Squibb Company

Healthcare · Drug Manufacturers - General

$61.39

Up+$1.09 (+1.78%)

Updated Oct 30, 2026, 11:04 PM

SID Score

5.9/10

Composite research score

Smart Money

50/100

Neutral

Market cap
104.23B
P/E ratio
17.28
Dividend yield
4.04%
52-week range
$53.15 – $68.64
Volume
14.77M
Avg. volume
16.54M

Price performance · BMY

BMY price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 29, 2026

BMY closed at $61.39 after 21 trading sessions, down 0.11% for the selected period.

Last close
$61.39
Period change
-0.11%
Period low
$56.67
Period high
$63.00
Daily close
View OHLC price history
BMY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 29, 2026$61.00$61.56$60.00$61.3914.77M
Oct 28, 2026$60.50$61.34$60.33$60.577.41M
Oct 27, 2026$61.21$61.64$60.92$61.557.78M
Oct 26, 2026$61.39$62.06$61.1145$61.617.84M
Oct 23, 2026$62.66$62.84$61.31$61.489.76M
Oct 22, 2026$61.46$63.59$61.04$63.0015.17M
Oct 21, 2026$61.50$61.8094$60.685$61.129.02M
Oct 20, 2026$59.93$61.815$59.83$61.6811.91M
Oct 19, 2026$59.40$59.8732$58.435$58.8311.55M
Oct 16, 2026$61.10$61.4273$59.54$59.7513.77M
Oct 15, 2026$60.67$62.25$60.39$60.5713.75M
Oct 14, 2026$56.81$59.385$56.58$59.2814.05M
Oct 13, 2026$57.775$58.0242$56.15$56.6716.96M
Oct 12, 2026$60.11$60.68$56.72$57.5822.57M
Oct 9, 2026$58.88$59.79$58.74$59.129.25M
Oct 8, 2026$59.10$59.94$58.73$59.5813.07M
Oct 7, 2026$59.45$60.10$59.01$59.7011.09M
Oct 6, 2026$58.94$59.595$58.635$59.599.89M
Oct 5, 2026$59.89$60.15$58.33$58.8119.24M
Oct 2, 2026$60.66$61.24$60.24$61.159.94M
Oct 1, 2026$62.20$62.61$61.25$61.4610.77M

Latest BMY news

The latest Smart Investors Daily articles mentioning BMY.

Stock researchCompany · Overview

BMY research

Overview

Company profile and research snapshot.

Company profile

Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Hold
Average target
$53.25
Implied upside
—
Analysts
17
BMY recent ratings
DateFirmRatingTarget
Oct 26, 2026Piper SandlerOverweight—
Oct 13, 2026Wells FargoEqual-Weight—
Oct 8, 2026Cantor FitzgeraldNeutral—
Oct 7, 2026Morgan StanleyUnderweight—
Oct 5, 2026Leerink PartnersMarket Perform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 24, 2026

Bristol Myers Squibb (BMY) Bets On AI Drug Discovery And Wider Trial Access

Bristol Myers Squibb (NYSE:BMY) has entered multi year AI drug development partnerships with Pathos AI and Tempus AI. The agreement gives Bristol Myers Squibb exclusive access to Pathos AI's discovery platform for neuroscience projects. Tempus AI will provide multi year data licensing that connects real world patient information with AI tools across Bristol Myers Squibb's pipeline. The company also launched a national collaboration with the Institute for Healthcare Improvement to broaden...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By